Short commentary
Integrating NOTCH Inhibitors with Standard Chemotherapeutic Drugs in Glioblastoma Multiforme Treatment: A Synergistic Approach
Author(s):
Abdul Hadi Khan*
Glioblastoma Multiforme (GBM) presents a significant obstacle in the field of cancer because of its aggressive nature and limited treatment options. Despite advances in surgical resection, radiation therapy, and chemotherapy, the median survival rate remains dishearteningly brief at 15 months. Glioblastoma Stem Cells (GSCs), particularly those expressing the CD133 marker, are acknowledged for their pivotal role in tumor growth and resistance to conventional therapies. The NOTCH signaling pathway is a crucial regulator of GSCs and plays a significant role in the induction of tumor heterogeneity and radioresistance. In this review, we explore the therapeutic potential of the NOTCH signaling pathway and evaluate various classes of NOTCH inhibitors inhibitors such as Gamma-Secretase Inhibitors (GSI), small interfering RNA (siRNA), and monoclonal antibodies. Although recent trials have sug.. Read More»
Select your language of interest to view the total content in your interested language
Annals of Medical and Health Sciences Research received 24805 citations as per google scholar report